Results 171 to 180 of about 70,621 (279)

Addressing Causality and Homogeneity Assumptions in Exposure‐Response Analyses

Clinical Pharmacology &Therapeutics, Volume 119, Issue 3, Page 703-712, March 2026.
Exposure‐response, or pharmacokinetic–pharmacodynamic (PKPD), analyses support many drug development decisions. It is typically applied without assessment of causality and homogeneity, where the latter refers to the assumption that the reason for variability in exposure is unimportant for the impact on response.
Mats O. Karlsson, Divya Brundavanam
wiley   +1 more source

Cost-Effectiveness Analysis of Trastuzumab-Emtansine as Adjuvant Therapy for HER2-Positive Early Breast Cancer with Residual Invasive Disease in Colombia. [PDF]

J Health Econ Outcomes Res
Samacá-Samacá D, Ballén D, Lombana M, Díaz-Puentes M, Cáceres-Maldonado SA, Saavedra J, Prieto-Pinto L.   +6 more
europepmc   +1 more source

Tumour‐targeted fluorescence‐guided surgery in gastrointestinal cancer: A systematic review of preclinical and clinical research

Clinical and Translational Medicine, Volume 16, Issue 3, March 2026.
Tumour‐targeted fluorescence‐guided surgery (Ttfgs) enhances intraoperative precision in gastrointestinal cancer treatment. Translation of (Ttfgs) into clinical practice is limited by heterogeneity, regulatory hurdles, biomarker variability and absence of phase III trials.
Aaya Darai, Evie H. M. Graus, Femke J. A. van der Stroom, Mark Rijpkema, Alexander Vahrmeijer, Denise E. Hilling, Johannes H. W. De Wilt, Merlijn Hutteman   +7 more
wiley   +1 more source

Indirect comparisons of tucatinib in combination with trastuzumab for patients with previously treated HER2-positive metastatic colorectal cancer. [PDF]

J Comp Eff Res
Watkins C, Simon C, Martin P, Leadley R, Redhead G, Neuberger E, Bartley K.   +6 more
europepmc   +1 more source

Artificial Intelligence and Prostate–Breast Cancer Biology: Recent Advances in Treatments and Perspectives — A Comprehensive Review

Health Science Reports, Volume 9, Issue 3, March 2026.
ABSTRACT Background and Aims The therapeutic limitations of conventional cancer treatment currently deployed are driving the development and creation of new nano‐drugs. Prostate cancer (PCa) is a prevalent clinical problem in older men with a significant global incidence, with 1.5 million cases reported in 2022.
Russell B. O. Ouma, Silas M. Ngari, Joshua K. Kibet   +2 more
wiley   +1 more source

Evaluating distant recurrence‐free survival and location of metastasis in HER2+ breast cancer by ER status

International Journal of Cancer, Volume 158, Issue 5, Page 1184-1192, 1 March 2026.
What's New? The prognostic significance of the presence or absence of human epidermal growth factor receptor 2 (HER2) and estrogen receptor (ER) in breast cancer is well‐established. However, the relationship of HER2 and ER with distant disease recurrence and metastasis location is less well understood.
Damien Kaukonen, Alexander Ploner, Erwei Zeng, Jenny Bergqvist, Kamila Czene   +4 more
wiley   +1 more source

The Conjugation of Antibodies to Heat Shock Protein 70 Activates Immune Responses Against Tumor Cells. [PDF]

Immunotargets Ther
Khosravi M, Rajaei A, Mohammadian B, Seyfi Abad Shapouri M.   +3 more
europepmc   +1 more source

Is Micronucleus Assay a Suitable Biomarker for Evaluating the Cancer Risk in Professionals Exposed to Antineoplastic Drugs? A Systematic Review

Journal of Applied Toxicology, Volume 46, Issue 3, Page 733-753, March 2026.
ABSTRACT The widespread use of antineoplastic drugs in cancer treatment has led to significant concerns regarding the potential health risks posed to healthcare professionals involved in the preparation, administration, and handling of these chemical compounds, including genotoxicity.
Thiago Guedes Pinto, Lorrany da Silva Avanci, Gabriel Carvalhal de Aguiar, Daniel Vitor de Souza, Patricia Ramos Cury, Ana Claudia Muniz Renno, Daniel Araki Ribeiro   +6 more
wiley   +1 more source

Selective fluorination of Fc glycans enhances antibody-mediated effector functions. [PDF]

Proc Natl Acad Sci U S A
Wang X, Gomozkova M, Li S, Banerjee B, Zong G, Missiakas D, Wang LX.   +6 more
europepmc   +1 more source

Artificial intelligence strategies for predicting kinase inhibitor resistance: A comprehensive review of methods, challenges, and future perspectives

Journal of Intelligent Medicine, Volume 3, Issue 1, Page 26-46, March 2026.
Abstract Kinase inhibitors are essential in targeted cancer therapy, yet resistance often emerges through secondary mutations, activation of compensatory signaling pathways, or drug‐efflux mechanisms. Artificial intelligence (AI) provides a workflow‐based strategy rather than a list of unrelated tools for predicting and addressing kinase‐inhibitor ...
Faris Hassan, Mohanad Ali Deifallah, Alaa Zaghloul, Rania Elgohary   +3 more
wiley   +1 more source